Fulltext

Glucosylceramide synthase inhibitors differentially affect expression of glycosphingolipids

Alam, Shahidul ; Fedier, André ; Kohler, Reto S. ; Jacob, Francis

In: Glycobiology, 2015, vol. 25, no. 4, p. 351-356

Ajouter à la liste personnelle
    Titre
    • Glucosylceramide synthase inhibitors differentially affect expression of glycosphingolipids
    Auteur
    • Alam, Shahidul. University Hospital Basel, University of Basel, Gynecological Research Group, Department of Biomedicine, Hebelstrasse 20, Basel 4031, Switzerland
    • Fedier, André. University Hospital Basel, University of Basel, Gynecological Research Group, Department of Biomedicine, Hebelstrasse 20, Basel 4031, Switzerland
    • Kohler, Reto S.. University Hospital Basel, University of Basel, Gynecological Research Group, Department of Biomedicine, Hebelstrasse 20, Basel 4031, Switzerland
    • Jacob, Francis. University Hospital Basel, University of Basel, Gynecological Research Group, Department of Biomedicine, Hebelstrasse 20, Basel 4031, Switzerland
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • Glycobiology, 2015, vol. 25, no. 4, p. 351-356. Oxford University Press
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:301446
    Summary
    Glucosylceramide synthase (GCS) catalyzes the first committed step in the biosynthesis of glucosylceramide (GlcCer)-related glycosphingolipids (GSLs). Although inhibitors of GCS, PPMP and PDMP have been widely used to elucidate their biological function and relevance, our comprehensive literature review revealed that the available data are ambiguous. We therefore investigated whether and to what extent GCS inhibitors affect the expression of lactosylceramide (LacCer), neolacto (nLc4 and P1), ganglio (GM1 and GD3) and globo (Gb3 and SSEA3) series GSLs in a panel of human cancer cell lines using flow cytometry, a commonly applied method investigating cell-surface GSLs after GCS inhibition. Their cell-surface GSL expression considerably varied among cell lines and more importantly, sublethal concentrations (IC10) of both inhibitors preferentially and significantly reduced the expression of Gb3 in the cancer cell lines IGROV1, BG1, HT29 and T47D, whereas SSEA3 was only reduced in BG1. Unexpectedly, the neolacto and ganglio series was not affected. LacCer, the precursor of all GlcCer-related GSL, was significantly reduced only in BG1 cells treated with PPMP. Future research questions addressing particular GSLs require careful consideration; our results indicate that the extent to which there is a decrease in the expression of one or more particular GSLs is dependent on the cell line under investigation, the type of GCS inhibitor and exposure duration